Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer

Multiparametric magnetic resonance imaging (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, the major limitations are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to...

Full description

Saved in:
Bibliographic Details
Main Authors: Madison T. Baxter, Christopher C. Conlin, Aditya Bagrodia, Tristan Barrett, Hauke Bartsch, Anja Brau, Matthew Cooperberg, Anders M. Dale, Arnaud Guidon, Michael E. Hahn, Mukesh G. Harisinghani, Juan F. Javier-DesLoges, Sophia C. Kamran, Christopher J. Kane, Joshua M. Kuperman, Daniel J.A. Margolis, Paul M. Murphy, Nabih Nakrour, Michael A. Ohliger, Rebecca Rakow-Penner, Ahmed Shabaik, Jeffry P. Simko, Clare M. Tempany, Natasha Wehrli, Sean A. Woolen, Jingjing Zou, Tyler M. Seibert
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:European Urology Open Science
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168324014344
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841533230576041984
author Madison T. Baxter
Christopher C. Conlin
Aditya Bagrodia
Tristan Barrett
Hauke Bartsch
Anja Brau
Matthew Cooperberg
Anders M. Dale
Arnaud Guidon
Michael E. Hahn
Mukesh G. Harisinghani
Juan F. Javier-DesLoges
Sophia C. Kamran
Christopher J. Kane
Joshua M. Kuperman
Daniel J.A. Margolis
Paul M. Murphy
Nabih Nakrour
Michael A. Ohliger
Rebecca Rakow-Penner
Ahmed Shabaik
Jeffry P. Simko
Clare M. Tempany
Natasha Wehrli
Sean A. Woolen
Jingjing Zou
Tyler M. Seibert
author_facet Madison T. Baxter
Christopher C. Conlin
Aditya Bagrodia
Tristan Barrett
Hauke Bartsch
Anja Brau
Matthew Cooperberg
Anders M. Dale
Arnaud Guidon
Michael E. Hahn
Mukesh G. Harisinghani
Juan F. Javier-DesLoges
Sophia C. Kamran
Christopher J. Kane
Joshua M. Kuperman
Daniel J.A. Margolis
Paul M. Murphy
Nabih Nakrour
Michael A. Ohliger
Rebecca Rakow-Penner
Ahmed Shabaik
Jeffry P. Simko
Clare M. Tempany
Natasha Wehrli
Sean A. Woolen
Jingjing Zou
Tyler M. Seibert
author_sort Madison T. Baxter
collection DOAJ
description Multiparametric magnetic resonance imaging (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, the major limitations are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to address these issues include use of biparametric magnetic resonance imaging (bpMRI) and advanced, quantitative magnetic resonance imaging (MRI) techniques. One such advanced technique is the Restriction Spectrum Imaging restriction score (RSIrs), an imaging biomarker that has been shown to improve quantitative accuracy of patient-level csPCa detection. Advanced Restriction imaging and reconstruction Technology for Prostate MRI (ART-Pro) is a multisite, multinational trial that aims to evaluate whether IV contrast can be avoided in the setting of standardized, state-of-the-art image acquisition, with or without addition of RSIrs. Additionally, RSIrs will be evaluated as a stand-alone, quantitative, objective biomarker. ART-Pro will be conducted in two stages and will include a total of 500 patients referred for multiparametric prostate MRI with a clinical suspicion of prostate cancer at the participating sites. ART-Pro-1 will evaluate bpMRI, mpMRI, and RSIrs on the accuracy of expert radiologists’ detection of csPCa and will evaluate RSIrs as a stand-alone, quantitative, objective biomarker. ART-Pro-2 will evaluate the same MRI techniques on the accuracy of nonexpert radiologists’ detection of csPCa, and findings will be evaluated against the expertly created dataset from ART-Pro-1. The primary endpoint is to evaluate whether bpMRI is noninferior to mpMRI among expert (ART-Pro-1) and nonexpert (ART-Pro-2) radiologists for the detection of grade group ≥2 csPCa. This trial is registered in the US National Library of Medicine Trial Registry (NCT number: NCT06579417) at ClinicalTrials.gov. Patient accrual at the first site (UC San Diego) began in December 2023. Initial results are anticipated by the end of 2026.
format Article
id doaj-art-4d83ed1c3d234d46864d870ea6653c6a
institution Kabale University
issn 2666-1683
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series European Urology Open Science
spelling doaj-art-4d83ed1c3d234d46864d870ea6653c6a2025-01-17T04:52:23ZengElsevierEuropean Urology Open Science2666-16832025-01-0171132143Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate CancerMadison T. Baxter0Christopher C. Conlin1Aditya Bagrodia2Tristan Barrett3Hauke Bartsch4Anja Brau5Matthew Cooperberg6Anders M. Dale7Arnaud Guidon8Michael E. Hahn9Mukesh G. Harisinghani10Juan F. Javier-DesLoges11Sophia C. Kamran12Christopher J. Kane13Joshua M. Kuperman14Daniel J.A. Margolis15Paul M. Murphy16Nabih Nakrour17Michael A. Ohliger18Rebecca Rakow-Penner19Ahmed Shabaik20Jeffry P. Simko21Clare M. Tempany22Natasha Wehrli23Sean A. Woolen24Jingjing Zou25Tyler M. Seibert26Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKDepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USAGE Healthcare, Chicago, IL, USADepartment of Urology, University of California San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USADepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA; Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, CA, USA; Halıcıoğlu Data Science Institute, University of California San Diego, La Jolla, CA, USAGE Healthcare, Chicago, IL, USADepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiology, Massachusetts General Hospital, Boston, MA, USADepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USADepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiology, Weill Cornell Medical College, New York, NY, USADepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Radiology, Massachusetts General Hospital, Boston, MA, USADepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USADepartment of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USADepartment of Pathology, UC San Diego School of Medicine, La Jolla, CA, USADepartment of Urology, University of California San Francisco, San Francisco, CA, USA; Department of Pathology, University of California San Francisco, San Francisco, CA, USADepartment of Radiology, Massachusetts General Hospital, Boston, MA, USADepartment of Radiology, Weill Cornell Medical College, New York, NY, USADepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USADepartment of Biostatistics, Herbert Wertheim School of Public Health & Human Longevity Science, University of California San Diego, La Jolla, CA, USADepartment of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, CA, USA; Department of Radiology, University of California San Diego School of Medicine, La Jolla, CA, USA; Department of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA; Department of Bioengineering, University of California San Diego Jacobs School of Engineering, La Jolla, CA, USA; Corresponding author. Altman Clinical and Translational Research Institute, 9500 Gilman Drive, #0861, La Jolla, CA 92093, USA. Tel. +1 (858) 246-5988; Fax: +1 (844) 321-6610‬‬‬‬‬‬‬‬‬‬Multiparametric magnetic resonance imaging (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, the major limitations are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to address these issues include use of biparametric magnetic resonance imaging (bpMRI) and advanced, quantitative magnetic resonance imaging (MRI) techniques. One such advanced technique is the Restriction Spectrum Imaging restriction score (RSIrs), an imaging biomarker that has been shown to improve quantitative accuracy of patient-level csPCa detection. Advanced Restriction imaging and reconstruction Technology for Prostate MRI (ART-Pro) is a multisite, multinational trial that aims to evaluate whether IV contrast can be avoided in the setting of standardized, state-of-the-art image acquisition, with or without addition of RSIrs. Additionally, RSIrs will be evaluated as a stand-alone, quantitative, objective biomarker. ART-Pro will be conducted in two stages and will include a total of 500 patients referred for multiparametric prostate MRI with a clinical suspicion of prostate cancer at the participating sites. ART-Pro-1 will evaluate bpMRI, mpMRI, and RSIrs on the accuracy of expert radiologists’ detection of csPCa and will evaluate RSIrs as a stand-alone, quantitative, objective biomarker. ART-Pro-2 will evaluate the same MRI techniques on the accuracy of nonexpert radiologists’ detection of csPCa, and findings will be evaluated against the expertly created dataset from ART-Pro-1. The primary endpoint is to evaluate whether bpMRI is noninferior to mpMRI among expert (ART-Pro-1) and nonexpert (ART-Pro-2) radiologists for the detection of grade group ≥2 csPCa. This trial is registered in the US National Library of Medicine Trial Registry (NCT number: NCT06579417) at ClinicalTrials.gov. Patient accrual at the first site (UC San Diego) began in December 2023. Initial results are anticipated by the end of 2026.http://www.sciencedirect.com/science/article/pii/S2666168324014344Biparametric magnetic resonance imagingClinical trialMultiparametric magnetic resonance imagingProstate cancerRestriction Spectrum ImagingRestriction Spectrum Imaging restriction score
spellingShingle Madison T. Baxter
Christopher C. Conlin
Aditya Bagrodia
Tristan Barrett
Hauke Bartsch
Anja Brau
Matthew Cooperberg
Anders M. Dale
Arnaud Guidon
Michael E. Hahn
Mukesh G. Harisinghani
Juan F. Javier-DesLoges
Sophia C. Kamran
Christopher J. Kane
Joshua M. Kuperman
Daniel J.A. Margolis
Paul M. Murphy
Nabih Nakrour
Michael A. Ohliger
Rebecca Rakow-Penner
Ahmed Shabaik
Jeffry P. Simko
Clare M. Tempany
Natasha Wehrli
Sean A. Woolen
Jingjing Zou
Tyler M. Seibert
Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer
European Urology Open Science
Biparametric magnetic resonance imaging
Clinical trial
Multiparametric magnetic resonance imaging
Prostate cancer
Restriction Spectrum Imaging
Restriction Spectrum Imaging restriction score
title Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer
title_full Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer
title_fullStr Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer
title_full_unstemmed Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer
title_short Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer
title_sort advanced restriction imaging and reconstruction technology for prostate magnetic resonance imaging art pro a study protocol for a multicenter multinational trial evaluating biparametric magnetic resonance imaging and advanced quantitative diffusion magnetic resonance imaging for the detection of prostate cancer
topic Biparametric magnetic resonance imaging
Clinical trial
Multiparametric magnetic resonance imaging
Prostate cancer
Restriction Spectrum Imaging
Restriction Spectrum Imaging restriction score
url http://www.sciencedirect.com/science/article/pii/S2666168324014344
work_keys_str_mv AT madisontbaxter advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT christophercconlin advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT adityabagrodia advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT tristanbarrett advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT haukebartsch advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT anjabrau advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT matthewcooperberg advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT andersmdale advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT arnaudguidon advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT michaelehahn advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT mukeshgharisinghani advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT juanfjavierdesloges advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT sophiackamran advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT christopherjkane advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT joshuamkuperman advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT danieljamargolis advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT paulmmurphy advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT nabihnakrour advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT michaelaohliger advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT rebeccarakowpenner advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT ahmedshabaik advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT jeffrypsimko advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT claremtempany advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT natashawehrli advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT seanawoolen advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT jingjingzou advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect
AT tylermseibert advancedrestrictionimagingandreconstructiontechnologyforprostatemagneticresonanceimagingartproastudyprotocolforamulticentermultinationaltrialevaluatingbiparametricmagneticresonanceimagingandadvancedquantitativediffusionmagneticresonanceimagingforthedetect